Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Piccart

Showing results (151-160 of 186) with videos related to

Pageof 19
Sort By:
ESMO Open|June 3, 2025
The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT studyL García-Estévez, A Bardia, H S Rugo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 18, 2017
Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trialL Buisseret, S Pommey, B Allard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 22, 2022
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) creditS F Oosting, J Barriuso, A Bottomley, et al.
Lancet (London, England)|December 14, 2011
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials, R Peto, C Davies, et al.
ESMO Open|June 12, 2026
Long-term outcomes and treatment response in early-stage invasive lobular carcinoma: insights from a nationwide population-based studyG Nader-Marta, L Ameye, D Martins-Branco, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 8, 2025
Adapting radiation therapy to immunotherapy: Delineation and treatment planning of pre-operative immune-modulating breast iSBRT in 151 patients treated in the randomized phase II Neo-CheckRay trialA De Caluwé, S Bellal, K Cao, et al.
Oncogene|February 28, 2024
Correction: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesionsC -R Pradeep, A Zeisel, W J Köstler, et al.
Oncogene|April 11, 2025
Correction: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesionsC -R Pradeep, A Zeisel, W J Köstler, et al.
Oncogene|December 6, 2011
Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesionsC-R Pradeep, A Zeisel, W J Köstler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 2014
Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trialH Bonnefoi, S Litière, M Piccart, et al.
Pageof 19

Showing results (151-160 of 186) with videos related to

Sort By:
Pageof 19
ESMO Open|June 3, 2025
The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT studyL García-Estévez, A Bardia, H S Rugo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 18, 2017
Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trialL Buisseret, S Pommey, B Allard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 22, 2022
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) creditS F Oosting, J Barriuso, A Bottomley, et al.
Lancet (London, England)|December 14, 2011
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials, R Peto, C Davies, et al.
ESMO Open|June 12, 2026
Long-term outcomes and treatment response in early-stage invasive lobular carcinoma: insights from a nationwide population-based studyG Nader-Marta, L Ameye, D Martins-Branco, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 8, 2025
Adapting radiation therapy to immunotherapy: Delineation and treatment planning of pre-operative immune-modulating breast iSBRT in 151 patients treated in the randomized phase II Neo-CheckRay trialA De Caluwé, S Bellal, K Cao, et al.
Oncogene|February 28, 2024
Correction: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesionsC -R Pradeep, A Zeisel, W J Köstler, et al.
Oncogene|April 11, 2025
Correction: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesionsC -R Pradeep, A Zeisel, W J Köstler, et al.
Oncogene|December 6, 2011
Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesionsC-R Pradeep, A Zeisel, W J Köstler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 2014
Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trialH Bonnefoi, S Litière, M Piccart, et al.
Pageof 19